MedTrace Logo

Immunomodulatory Effects of Subcutaneous Progesterone in Patients Affected by Autoimmune Diseases

NCT04665232 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 18

Last updated 2024-05-28

No results posted yet for this study

Summary

This study evaluates the immunomodulatory effects of subcutaneous progesterone in patients undergoing IVF by determination of anti-nuclear antibodies (ANA),extractable nuclear antigen antibodies (ENA),anti- neutrophil cytoplasmic antibodies(ANCA),anti-DNA antibodies, anti-cardiolipin antibodies (ACA),Lupus anticoagulant antibodies (LAC) and C3 and C4 fractions of complement on the day of beta hCG dosage and during the eigth week of gestation.

Conditions

Interventions

DRUG

aqueous subcutaneous progesterone

25 mg/die of aqueous subcutaneous progesterone from the day of oocytes retrieval for two weeks.

Sponsors & Collaborators

  • San Carlo Public Hospital, Potenza, Italy

    lead OTHER

Principal Investigators

  • Assunta Iuliano, MD,PhD · San Carlo Public Hospital, Potenza, Italy

Eligibility

Min Age
18 Years
Max Age
42 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2017-04-30
Completion
2017-04-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04665232 on ClinicalTrials.gov